KINNATE BIOPHARMA INC's ticker is KNTE and the CUSIP is 49705R105. A total of 73 filers reported holding KINNATE BIOPHARMA INC in Q4 2021. The put-call ratio across all filers is - and the average weighting 1.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $708 | -30.9% | 505,956 | +49.8% | 0.00% | 0.0% |
| Q2 2023 | $1,024 | +48.2% | 337,800 | +205.7% | 0.00% | 0.0% |
| Q1 2023 | $691 | +9.5% | 110,500 | +6.9% | 0.00% | 0.0% |
| Q4 2022 | $631 | -99.9% | 103,400 | +2.9% | 0.00% | -50.0% |
| Q3 2022 | $1,201,000 | -0.4% | 100,500 | +5.1% | 0.00% | +100.0% |
| Q2 2022 | $1,206,000 | +348.3% | 95,600 | +300.0% | 0.00% | – |
| Q1 2022 | $269,000 | -50.0% | 23,900 | +2.3% | 0.00% | -100.0% |
| Q3 2021 | $538,000 | -35.6% | 23,358 | -34.9% | 0.00% | 0.0% |
| Q2 2021 | $836,000 | – | 35,900 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management IV, LLC | 9,671,643 | $225,156,000 | 30.44% |
| Vida Ventures Advisors, LLC | 2,747,433 | $63,960,000 | 16.04% |
| Foresite Capital Management V, LLC | 875,001 | $20,370,000 | 8.01% |
| VR Adviser, LLC | 1,473,014 | $34,292,000 | 4.16% |
| Logos Global Management LP | 1,329,602 | $30,953,000 | 2.60% |
| RA Capital Management | 3,593,052 | $83,646,000 | 1.34% |
| Orbimed Advisors | 3,847,929 | $89,580,000 | 0.91% |
| Boxer Capital, LLC | 1,065,939 | $24,815,000 | 0.88% |
| HARVARD MANAGEMENT CO INC | 498,001 | $11,593,000 | 0.67% |
| HighVista Strategies LLC | 33,391 | $777,000 | 0.55% |